MHRAsafety guidance65% confidence
Draft rare disease therapies regulatory framework
Source: MHRA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for TAPUR Study Evaluates Targeted Therapies in Advanced Cancer with Genomic Variant.
Regulatory Analysis
MHRA are seeking feedback on a proposed framework for rare disease therapies.
Supporting Context
- Therapeutic area
- Oncology · Targeted Therapy
- Sub-indication
- General
Related signal: TAPUR Study Evaluates Targeted Therapies in Advanced Cancer with Genomic Variants